OIPE IAP76 AUG 27 2007 PATENT & TRADEMARK OFFICE

Used In Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete If Known	
Application Number	10/680,988-Conf. #6477
Filing Date	October 7, 2003
First Named Inventor	Andrew R. MARKS
Art Unit	1646
Examiner Name	R. Li
Attorney Docket Number	19240.593US1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/R.L./	AA*	US-5,866,341	02-02-1999	Spinella et al.	
/R.L./	AB*	US-6,989,275-A1	01-24-2006	Waggoner	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
/R.L./	CA**	Bidasee et al., "Chronic Diabetes Increases Advanced Glycation End Products on Cardiac Ryanodine Receptors/Calcium-Release Channels," Diabetes, Vol 52, pp. 1825-1836	
	CB**	Bidasee et al., "Diabetes Increases Formation of Advanced Glycation End Products on Sarco (endo) plasmic Reticulum Ca2+-ATPase," Diabetes, Vol 53, pp. 463-473 (2004)	
	CC**	Bruton et al., "Ryanodine receptors of pancreatic β-cells mediate a distinct context-dependent signal for insulin secretion," the FASEB Journal, Vol 17, pp. 301-303 (2003)	
	CD**	Buijs et al., "β-Adrenergic activation reveals impaired cardia calcium handling at early stage of diabetes," Life Sciences, Vol 76, pp. 1083-1098 (2005)	
	CE**	Dyachok et al., "Ca2+-induced Ca2+ release by activation of inositol 1,4,5-trisphosphate receptors in primary pancreatic β-cells," Cell Calcium, Vol 36, pp. 1-9 (2004)	
	CF**	Dyachok et al., "Ca2+-induced Ca2+ Release via Inositol 1,4,5-trisphosphate Receptors Is Amplified by Protein Kinase and Triggers Exocytosis in Pancreatic β-Cells," The Journal of Biological Chemistry, Vol. 279, No 44, pp. 45455-45461 (2004)	
	CG**	Eisner et al., "The Ryanodine Receptor: Cause or Consequence of Diabetic Heart Failure ?," J. Moll Cell Cardiol, Vol 32, pp. 1377-1378 (2000)	
	CH**	Holz et al., " cAMP-dependent Mobilization of Intracellular Ca2+ Stores by Activation of Ryanodine Receptors in Pancreatic β-Cells," The Journal of Biological Chemistry, Vol 274, pp. 14147-14156 (1999)	
	CI**	International Search Report and Written Opinion from PCT/US2005/10056, June 5, 2007	
	CJ**	Islam et al., "Effects of caffeine on cytoplasmic free Ca2+ concentration in pancreatic β-cells are mediated by interaction with ATP-sensitive K+ channels and L-type voltage-gated Ca2+ channels but not ryanodine receptor," Biochem. J., Vol. 306, pp. 679-686 (1995)	
	CK**	Islam et al., "In situ activation of the type 2 ryanodine receptor in pancreatic beta cells requires cAMP-dependent phosphorylation," Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 6145-6150 (1998)	
/R.L./	CL**	Islam S., " Perspectives in Diabetes. The Ryanodine Receptor Calcium Channel of β-Cells.	

Examiner Signature	/Ruixiang Li/	Date Considered	11/11/2007

6337768

Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/680,988-Conf. #6477
				Filing Date	October 7, 2003
				First Named Inventor	Andrew R. MARKS
				Art Unit	1646
(Use as many sheets as necessary)				Examiner Name	R. Li
Sheet	2	of	2	Attorney Docket Number	19240.593US1

/R.L./		Molecular Regulation and Physiological Significance," Diabetes, Vol 51, pp. 1299-1309 (2002)	
/R.L./	CM**	Johnson et al., "Ryanodine receptors in human pancreatic β cells: localization and effects on insulin secretion1," the FASEB Journal, Vol 18, pp. 878-880 (2004)	
	CN**	Johnson et al., "RyR2 and Calpain-10 Delineate a Novel Apoptosis Pathway in Pancreatic Islets," The Journal of Biological Chemistry, Vol 279, pp. 24794-24802 (2004)	
	CO**	Kang et al., "A cAMP and Ca2+ coincidence detector in support of Ca2+-induced Ca2+ release in mouse pancreatic β cells," J. Physiol, Vol 566, pp. 173-188 (2005)	
	CP**	Kang et al., "cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic β-cells," Journal of Physiology, Vol 536.2, pp. 375-385 (2001)	
	CQ**	Lehnart et al., "Phosphodiesterase 4D associates with the cardiac calcium release channel (Ryanodine Receptor) and protects from Hypertrophy and heart failure", Circulation, Vol. 110, No 17 Suppl. S, pp. 227-228 (October 26, 2004)	
	CR**	Liu et al., "Crosstalk between the cAMP and Inositol Trisphosphate-Signalling Pathways in Pancreatis β-Cells," Archives of Biochemistry and Biophysics, Vol 334, pp.295-302 (1996)	
	CS**	Mitchell et al., "Ryanodine Receptor Type I and Nicotinic Acid Adenine Dinucleotide Phosphate Receptors Mediate Ca2+ Release from Insulin-containing Vesicles in Living Pancreatic β-Cells (MIN6)," The Journal of Biological Chemistry, Vol 278, pp. 11057-11064 (2003)	
	CT**	Pereira et al., "Mechanisms of [Ca2+]i Transient Decrease in Cardiomyopathy of db/db Type 2 Diabetic Mice," Diabetes, Vol 55, pp. 608-615 (2006)	
	CU**	Shao et al., " Dyssynchronous (non-uniform) Ca2+ release in myocytes from streptozotocin-induced diabetic rats," Journal of Molecular and Cellular Cardiology, Vol 42, pp. 234-246 (2007)	
	CV**	Takasawa et al., " Cyclic ADP-ribose and Inositol 1,4,5-Trisphosphate as Alternate Second Messengers for Intracellular Ca2+ Mobilization in Normal and Diabetic β-Cells," The Journal of Biological Chemistry, Vol 273, pp. 2497-2500 (1998)	
	CW**	Varadi et al., "Dynamic Imaging of Endoplasmic Reticulm Ca2+ Concentration in Insulin-Secreting MIN6 Cells Using Recombinant Target Cameleons. Role of Sarco (endo) plasmic Reticulum Ca2+ -ATPase (SERCA)-2 and Ryanodine Receptors," Diabetes, Vol 51, Suppl. 1, pp. S190-S201 (2002)	
	CX**	Woolcott et al., "Arachidonic acid is a physiological activator of the ryanodine receptor in pancreatic β-cells," Cell Calcium, Vol 39, pp. 529-537 (2006)	
	CY**	Yaras et al., "Effects of Diabetes on Ryanodine Receptor Ca Release Channel (RyR2) and Ca2+ Homeostasis in Rat Heart," Diabetes, Vol 54, pp. 3082-3088 (2005)	
	CZ**	Yaras et al., "Restoration of Diabetes-induced abnormal local Ca2+ release in cardiomyocytes by angiotensin II receptor blockade," Am J. Physiol Heart Circ Physiol, Vol 292, pp. H912-H920 (2007)	
/R.L./	CA1**	Zhang et al., "Growth Hormone Promotes Ca+2-induces Ca2+ Release in Insulin-Secreting Cells by Ryanodine Receptor Tyrosine Phosphorylation," Molecular Endocrinology, Vol 18, pp. 1658-1669 (2004)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Ruixiang Li/	Date Considered	11/11/2007

6337768

US1DOCS 6337768v1

OIPE IAP2
MAR 3 0 2007
PATENT & TRADEMARK OFFICE

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/680,988-Conf. #6477
Filing Date	October 7, 2003
First Named Inventor	Andrew R. MARKS
Art Unit	1646
Examiner Name	R. Li
Attorney Docket Number	0019240.00593US1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/R.L./	AA*	US-20050186640-A1	08-25-2005	Marks et al.	
	AB*	US-20050187386-A1	08-25-2005	Marks et al.	
	AC*	US-20060194767-A1	08-31-2006	Marks et al.	
	AD*	US-20060293266-A1	12-28-2006	Marks	
/R.L./	AE*	US-20070049572-A1	03-01-2007	Marks et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
/R.L./	BA	WO-04/080283	09-23-2004	The Trustees of Columbia University in the city of New York		
	BB	WO-05/002518	01-13-2005	The Trustees of Columbia University in the city of New York		
	BC	WO-05/037195	04-28-2005	The Trustees of Columbia University in the city of New York		
	BD	WO-05/094457	10-13-2005	The Trustees of Columbai University in the city of New York		
	BE	WO-06/071603	07-06-2006	The Trustees of Columbia University in the city of New York		
	BF	WO-06/101497	09-28-2006	The Trustees of Columbia University in the city of New York		
	BG	WO-06/101496	09-28-2006	The Trustees of Columbia University in city of New York		
/R.L./	BH	WO-07/024717	03-01-2007	The Trustees of Columbia University in the city of New York		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. [2] Applicant's unique citation designation number (optional). [3] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [4] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [5] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [6] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [7] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]

Examiner Signature	/Ruixiang Li/	Date Considered	11/13/2007

6131246

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	2

Complete if Known	
Application Number	10/680,988-Conf. #6477
Filing Date	October 7, 2003
First Named Inventor	Andrew R. MARKS
Art Unit	1646
Examiner Name	R. Li
Attorney Docket Number	0019240.00593US1

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Ruixiang Li/	Date Considered	/Ruixiang Li/

OIPE IAP2
MAR 05 2007
PATENT & TRADEMARK OFFICE

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 9

Complete if Known	
Application Number	10/680,988-Conf. #6477
Filing Date	October 7, 2003
First Named Inventor	Andrew R. MARKS
Art Unit	1646
Examiner Name	R. Li
Attorney Docket Number	0019240.00593US1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/R.L./	AA*	US-20050213426-A1	09-29-2005	Midas et al.	
	AB*	US-5,457,182	10-10-1995	Wiederrecht et al.	
	AC*	US-6,313,113	11-06-2001	Lohray et al.	
	AD*	US-5,153,184	10-06-1992	Reifschneider et al.	
	AE*	US-6,683,083	01-27-2004	Kaneko et al.	
	AF*	US-6,977,252	12-20-2005	Kaneko et al.	
	AG*	US-6,649,366-A1	11-18-2003	Chubinskaya et al.	
	AH*	US-2002/0042405-A1	04-11-2002	Schuh	
	AI*	US-20020052358-A1	05-02-2002	Chubinskaya et al.	
	AJ*	US-20030220310-A1	11-27-2003	Schuh	
	AK*	US-20030220312-A1	11-27-2003	Schuh	
	AL*	US-20030055027-A1	03-20-2003	Schun	
	AM*	US-20040053919-A1	03-18-2004	Chubinskaya et al.	
	AN*	US-20020132001-A1	09-19-2002	Garthwaite et al.	
	AO*	US-20050192259-A1	09-01-2005	Garthwaite et al.	
	AP*	US-20070010571-A1	01-11-2007	Garvey et al.	
	AQ*	US-20060135506-A1	06-22-2006	Stephenson et al.	
	AR*	US-20060189603-A1	08-24-2006	Garvey et al.	
	AS*	US-20050009733-A1	01-13-2005	Stephenson et al.	
	AT*	US-20050059655-A1	03-17-2005	Garvey et al.	
	AU*	US-20050159403-A1	07-21-2005	Stephenson et al.	
	AV*	US-20040229803-A1	11-18-2004	Stephenson et al.	
	AW*	US-20030044845-A1	03-06-2003	Jenkins et al.	
	AX*	US-6,830,896-A1	12-14-2004	Kaneko et al.	
	AY*	US-6,906,072	06-14-2005	Yamamoto et al.	
	AZ*	US-5,767,247	06-16-1998	Kaneko et al.	
	AA1*	US-5,304,558	04-19-1994	Kaneko et al.	
	AB1*	US-20060084658-A1	04-20-2006	Yamamoto et al.	
	AC1*	US-20040220193-A1	11-04-2004	Yamamoto et al.	
	AD1*	US-20030064406-A1	04-03-2003	Kaneko et al.	
	AE1*	US-20030124637-A1	07-03-2003	Kaneko et al.	
	AF1*	US-6,812,252-A1	11-02-2004	Ikawa et al.	
	AG1*	US-6,897,295	05-24-2005	Nagata et al.	
	AH1*	US-6,962,926-A1	11-08-2005	Laborde et al.	
	AI1*	US-6,998,469-A1	02-14-2006	Tandon et al.	
	AJ1*	US-6,271,353	08-07-2001	Nakamura et al.	
	AK1*	US-6,255,472	07-03-2001	Tokino et al.	
	AL1*	US-6,316,485	11-13-2001	Nakamura et al.	
	AM1*	US-6,348,334	02-19-2002	Nagata et al.	
	AN1*	US-5,753,649	05-19-1998	Tahara et al.	
	AO1*	US-6,130,060	10-10-2000	Nakamura, deceased et al.	
	AP1*	US-6,184,352	02-06-2001	Nakamura et al.	
	AQ1*	US-5,179,125	01-12-1993	Mimura et al.	
	AR1*	US-5,210,266	05-11-1993	Mimura et al.	
	AS1*	US-5,387,684	02-07-1995	Inoue et al.	

Examiner Signature	/Ruixiang Li/	Date Considered	11/13/2007

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 9

Complete if Known	
Application Number	10/680,988-Conf. #6477
Filing Date	October 7, 2003
First Named Inventor	Andrew R. MARKS
Art Unit	1646
Examiner Name	R. Li
Attorney Docket Number	0019240.00593US1

/R.L./	AT1*	US-5,478,832	12-26-1995	Inoue et al.		
	AU1*	US-5,523,410	06-04-1996	Kagara et al.		
	AV1*	US-5,593,988	01-14-1997	Tahara et al.		
	AW1*	US-5,665,881	09-09-1997	Inoue et al.		
	AX1*	US-4,567,254	01-28-1986	Kataoka et al.		
	AY1*	US-4,658,055	04-14-1987	Onuki et al.		
	AZ1*	US-4,849,535	07-18-1989	Naora et al.		
	AA2*	US-20050171196-A1	08-04-2005	Fujii et al.		
	AB2*	US-20030186885-A1	10-02-2003	Tandon et al.		
	AC2*	US-20040198719-A1	10-07-2004	Laborde et al.		
	AD2*	US-20050074762-A1	04-07-2005	Nakamura et al.		
	AE2*	US-20030191323-A1	10-09-2003	Ikawa et al.		
	AF2*	US-20030181764-A1	09-25-2003	Ikawa et al.		
	AG2*	US-7,135,466-A1	11-14-2006	Sakai et al.		
	AH2*	US-6,750,255-A1	06-15-2004	Sakai et al.		
	AI2*	US-6,821,987-A1	11-23-2004	Kubo et al.		
	AJ2*	US-6,939,895-A1	09-06-2005	Sakai et al.		
	AK2*	US-6,362,231	03-26-2002	Sakai et al.		
	AL2*	US-6,500,816	12-31-2002	Ekimoto et al.		
	AM2*	US-20060258701-A1	11-16-2006	Mitsuya et al.		
	AN2*	US-20060211717-A1	09-21-2006	Sakai et al.		
	AO2*	US-20040132727-A1	07-08-2004	Sakai et al.		
	AP2*	US-20040229876-A1	11-18-2004	Kubo et al.		
	AQ2*	US-20020107406-A1	08-08-2002	Sakai et al.		
	AR2*	US-20030087907-A1	05-08-2003	Kubo et al.		
	AS2*	US-20030176485-A1	09-18-2003	Sakai et al.		
	AT2*	US-20030144526-A1	07-31-2003	Sakai et al.		
	AU2*	US-7,163,952-A1	01-16-2007	Inaba et al.		
	AV2*	US-6,753,346-A1	06-22-2004	Shinkai et al.		
	AW2*	US-6,803,039-A1	10-12-2004	Tsuji et al.		
	AX2*	US-6,869,975-A1	03-22-2005	Abe et al.		
	AY2*	US-7,030,225	04-18-2006	Tamatani et al.		
	AZ2*	US-7,045,615-A1	05-16-2006	Tamatani et al.		
	AA3*	US-7,112,655	09-26-2006	Tamatani et al.		
	AB3*	US-6,235,730	05-22-2001	Sato et al.		
	AC3*	US-6,426,365	07-30-2002	Shinkai et al.		
	AD3*	US-6,410,561	06-25-2002	Shinkai et al.		
	AE3*	US-6,583,157-A1	06-24-2003	McGee et al.		
	AF3*	US-6,562,618	05-13-2003	Tamatani et al.		
	AG3*	US-6,562,828	05-13-2003	Katoh et al.		
	AH3*	US-5,719,155	02-17-1998	Cho et al.		
	AI3*	US-5,750,696	05-12-1998	Shibata et al.		
	AJ3*	US-5,824,862	10-20-1998	Hiyoshi et al.		
	AK3*	US-5,807,850	09-15-1998	Nakamura et al.		
	AL3*	US-5,792,655	08-11-1998	Watanabe et al.		
	AM3*	US-5,142,647	08-25-1992	Nakagawa et al.		
/R.L./	AN3*	US-5,214,056	05-25-1993	Haruta et al.		

Examiner Signature	/Ruixiang Li/	Date Considered	11/13/2007

6090139

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 9

Complete if Known	
Application Number	10/680,988-Conf. #6477
Filing Date	October 7, 2003
First Named Inventor	Andrew R. MARKS
Art Unit	1646
Examiner Name	R. Li
Attorney Docket Number	0019240.00593US1

/R.L./	AO3*	US-5,204,462	04-20-1993	Kobayashi et al.		
	AP3*	US-5,304,380	04-19-1994	Miyajima et al.		
	AQ3*	US-5,260,286	11-09-1993	Lawson et al.		
	AR3*	US-5,332,734	07-26-1994	Kobayashi et al.		
	AS3*	US-5,354,758	10-11-1994	Lawson et al.		
	AT3*	US-5,476,780	12-19-1995	Watanabe et al.		
	AU3*	US-5,624,961	04-29-1997	Ban et al.		
	AV3*	US-4,723,012	02-02-1988	Matsumoto et al.		
	AW3*	US-4,845,065	07-04-1989	Sugimori et al.		
	AX3*	US-4,841,055	06-20-1989	Matsumoto et al.		
	AY3*	US-20050187221-A1	08-25-2005	Matsuda et al.		
	AZ3*	US-20050277649-A1	12-15-2005	DeGraffenreid et al.		
	AA4*	US-20050035939-A1	02-17-2005	Akiyama		
	AB4*	US-20060035882-A1	02-16-2006	Koga et al.		
	AC4*	US-20060014768-A1	01-19-2006	Kawasaki et al.		
	AD4*	US-20060030565-A1	02-09-2006	Shinkai et al.		
	AE4*	US-20060059575-A1	03-16-2006	Kusunoki et al.		
	AF4*	US-20060223133-A1	10-05-2006	Tamatani et al.		
	AG4*	US-20060205731-A1	09-14-2006	Kodama et al.		
	AH4*	US-20060122181-A1	06-08-2006	Ikemoto et al.		
	AI4*	US-20060270705-A1	11-30-2006	Yonemori et al.		
	AJ4*	US-20070010670-A1	01-11-2007	Hirata et al.		
	AK4*	US-20040073012-A1	04-15-2004	Tamatani et al.		
	AL4*	US-20040132658-A1	07-08-2004	Tamatani et al.		
	AM4*	US-20040120945-A1	06-24-2004	Tamatani et al.		
	AN4*	US-20040017409-A1	01-29-2004	Mizutani et al.		
	AO4*	US-20040180052-A1	09-16-2004	Tsuji et al.		
	AP4*	US-20040171613-A1	09-02-2004	Iwamura et al.		
	AQ4*	US-20040151718-A1	08-05-2004	Tamatani et al.		
	AR4*	US-20040151720-A1	08-05-2004	Tamatani et al.		
	AS4*	US-20040151669-A1	08-05-2004	Tamatani et al.		
	AT4*	US-20040146991-A1	07-29-2004	Tsuji et al.		
	AU4*	US-20040146506-A1	07-29-2004	Tamatani et al.		
	AV4*	US-20040209871-A1	10-21-2004	Fox et al.		
	AW4*	US-20040242683-A1	12-02-2004	Urata et al.		
	AX4*	US-20040229957-A1	11-18-2004	Shinkai et al.		
	AY4*	US-20040229790-A1	11-18-2004	Tezuka et al.		
	AZ4*	US-20040229788-A1	11-18-2004	Tamatani et al.		
	AA5*	US-20040225018-A1	11-11-2004	Sunami et al.		
	AB5*	US-20050020668-A1	01-27-2005	Urata et al.		
	AC5*	US-20050070545-A1	03-31-2005	Fox et al.		
	AD5*	US-20050059810-A1	03-17-2005	Maeda et al.		
	AE5*	US-20050051181-A1	03-10-2005	Okamoto		
	AF5*	US-20020115831-A1	08-22-2002	Tamatani et al.		
	AG5*	US-20020156242-A1	10-24-2002	Tamatani et al.		
	AH5*	US-20020151685-A1	10-17-2002	Tamatani et al.		
/R.L./	AI5*	US-20030083472-A1	05-01-2003	Tamatani et al.		

Examiner Signature	/Ruixiang Li/	Date Considered	11/13/2007

6090139

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 9

Complete if Known	
Application Number	10/680,988-Conf. #6477
Filing Date	October 7, 2003
First Named Inventor	Andrew R. MARKS
Art Unit	1646
Examiner Name	R. Li
Attorney Docket Number	0019240.00593US1

/R.L./	AJ5*	US-20030055087-A1	03-20-2003	Shinkai et al.		
	AK5*	US-20030232855-A1	12-18-2003	Iwamura et al.		
	AL5*	US-20030092708-A1	05-15-2003	Shinkai et al.		
	AM5*	US-20040006099-A1	01-08-2004	Katoh et al.		
	AN5*	US-7,029,671	04-18-2006	Koezuka et al.		
	AO5*	US-5,508,293	04-16-1996	Okawara et al.		
	AP5*	US-6,660,837	12-09-2003	Kaibuchi et al.		
	AQ5*	US-6,824,973-A1	11-30-2004	Tang et al.		
	AR5*	US-6,673,904-A1	01-06-2004	Nishikawa et al.		
	AS5*	US-6,890,531	05-10-2005	Horie et al.		
	AT5*	US-6,964,975-A1	11-15-2005	Ueno et al.		
	AU5*	US-7,064,194-A1	06-20-2006	Misawa et al.		
	AV5*	US-7,041,870-A1	05-09-2006	Tomizuka et al.		
	AW5*	US-6,338,955-A1	01-15-2002	Oguri et al.		
	AX5*	US-6,391,595	05-21-2002	Kato et al.		
	AY5*	US-6,632,976	10-14-2003	Tomizuka et al.		
	AZ5*	US-5,780,441	07-14-1998	Higa et al.		
	AA6*	US-5,906,819	05-25-1999	Kaibuchi et al.		
	AB6*	US-6,013,499	01-11-2000	Narumiya et al.		
	AC6*	US-6,111,072	08-29-2000	Narumiya et al.		
	AD6*	US-5,166,347	11-24-1992	Izawa et al.		
	AE6*	US-5,223,508	06-29-1993	Izawa et al.		
	AF6*	US-5,272,164	12-21-1993	Izawa et al.		
	AG6*	US-5,413,929	05-09-1995	Ishizaki et al.		
	AH6*	US-5,453,282	09-26-1995	Kanauchi et al.		
	AI6*	US-5,654,001	08-05-1997	Kanauchi et al.		
	AJ6*	US-4,888,418	12-19-1989	Kawai et al.		
	AK6*	US-20050177884-A1	08-11-2005	Tomizuka et al.		
	AL6*	US-20050159365-A1	07-21-2005	Serizawa et al.		
	AM6*	US-20050255546-A1	11-17-2005	Nishikawa		
	AN6*	US-20060041945-A1	02-23-2006	Robl et al.		
	AO6*	US-20060037093-A1	02-16-2006	Tomizuka et al.		
	AP6*	US-20060026698-A1	02-02-2006	Tomizuka et al.		
	AQ6*	US-20060078992-A1	04-13-2006	Misawa et al.		
	AR6*	US-20060123490-A1	06-08-2006	Kakitani et al.		
	AS6*	US-20060011375-A1	01-19-2006	Sugimoto et al.		
	AT6*	US-20060185025-A1	08-17-2006	Oshimura et al.		
	AU6*	US-20060167043-A1	07-27-2006	Iwakubo et al.		
	AV6*	US-20060233902-A1	10-19-2006	Yajima et al.		
	AW6*	US-20060217426-A1	09-28-2006	Eto et al.		
	AX6*	US-20040073957-A1	04-15-2004	Tomizuka et al.		
	AY6*	US-20040175814-A1	09-09-2004	Kato et al.		
	AZ6*	US-20040235162-A1	11-25-2004	Sato		
	AA7*	US-20050032210-A1	02-10-2005	Sato et al.		
	AB7*	US-20020199213-A1	12-26-2002	Tomizuka et al.		
	AC7*	US-6,914,158-A1	07-05-2005	Webber et al.		
/R.L./	AD7*	US-6,951,889-A1	10-04-2005	Hansen, Jr. et al.		

Examiner Signature	/Ruixiang Li/	Date Considered	11/13/2007

6090139

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 9

Complete if Known	
Application Number	10/680,988-Conf. #6477
Filing Date	October 7, 2003
First Named Inventor	Andrew R. MARKS
Art Unit	1646
Examiner Name	R. Li
Attorney Docket Number	0019240.00593US1

/R.L./	AE7*	US-7,005,450-A1	02-28-2006	Durley et al.	
	AF7*	US-7,102,013-A1	09-05-2006	Webber et al.	
	AG7*	US-6,756,406-A1	06-29-2004	Durley et al.	
	AH7*	US-6,787,668-A1	09-07-2004	Pitzele et al.	
	AI7*	US-6,828,456-A1	12-07-2004	Hansen, Jr. et al.	
	AJ7*	US-6,852,753-A1	02-08-2005	Koeller et al.	
	AK7*	US-6,403,830-A1	06-11-2002	Webber et al.	
	AL7*	US-6,465,686-A1	10-15-2002	Grapperhaus et al.	
	AM7*	US-6,465,518-A1	10-15-2002	Hansen, Jr. et al.	
	AN7*	US-6,495,544-A1	12-17-2002	Hansen, Jr. et al.	
	AO7*	US-6,545,170-A1	04-08-2003	Pitzele et al.	
	AP7*	US-6,586,474-A1	07-01-2003	Webber et al.	
	AQ7*	US-20050256199-A1	11-17-2005	Durley et al.	
	AR7*	US-20050070543-A1	03-31-2005	Stephenson	
	AS7*	US-20050113451-A1	05-26-2005	Hansen et al.	
	AT7*	US-20050165106-A1	07-28-2005	Webber et al.	
	AU7*	US-20040192584-A1	09-30-2004	McMahon et al.	
	AV7*	US-20040186178-A1	09-23-2004	Webber et al.	
	AW7*	US-20030199701-A1	10-23-2003	Webber et al.	
	AX7*	US-20030199482-A1	10-23-2003	Seibert et al.	
/R.L./	AY7*	US-20030195218-A1	10-16-2003	Koeller et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[2]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
/R.L./	BA	WO-99/16758	04-08-1999	Dr. Reddy's Research Foundation		
/R.L./	BB	WO-98/45291	10-15-1998	Dr. Reddy's Research Foundation		
/R.L./	BC	EP-1743895	01-17-2007	Aetas Pharma Col., Ltd.		
/R.L./	BD	EP-0467325	01-22-1992	Syntex (USA) Inc.		
/R.L./	BE	WO-05/105793	11-10-2005	Aetas Pharma Co. Ltd		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
/R.L./	CA	Bristow, Michael R. et al. "Beta-Adrenergic Neuroeffector Abnormalities in the Failing Human Heart are Produced by Local Rather Than Systemic Mechanisms." J. Clin. Invest., Vol. 89, pp. 803-815 (March 1992).	
/R.L./	CB	Kohno et al., "A New Cardioprotective Agent, JTV-519, Improves Defective Channel Gating of	

Examiner Signature	/Ruixiang Li/	Date Considered	11/13/2007

6090139

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 9

Complete If Known	
Application Number	10/680,988-Conf. #6477
Filing Date	October 7, 2003
First Named Inventor	Andrew R. MARKS
Art Unit	1646
Examiner Name	R. Li
Attorney Docket Number	0019240.00593US1

/R.L./		Ryanodine Receptor in Heart Failure. " Am. J. Physiol Heart Circ. Physiol., Vol. 284, No. 3, pp. H1035-H1042. First published November 14, 2002. (March 2003)	
	CC	Marks et al. "Involvement of the Cardiac Ryanodine Receptor/Calcium Release Channel in Catecholaminergic Polymorphic Ventricular Tachycardia." J. Cell. Physiol., Vol. 190, pp. 1-6. First published October 26, 2001 (2002).	
	CD	Reiken et al. "Protein Kinase A Phosphorylation of the Cardiac Calcium Release Channel (Ryanodine Receptor) in Normal and Failing Hearts. Role of Phosphatases and Response to Isoproterenol." J. Biol. Chem., Vol. 278, No. 1, pp. 444-453. (2003).	
	CE	Szabo et al. "Synthesis and Transformations of 4,5-Dihydro-1,4-benzothiazepin-3(2H)-one Derivatives1,2)." Chemische Berichte., Vol. 119, No. 9, pp. 2904-2913. (1986).	
	CF	Szabo, Janos et al., "Synthesis and Spectroscopic Investigations of 1,4-benzothiazepine derivatives." Can. J. Chem, Vol. 65, pp. 175-181. (1987).	
	CG	Haut, Donahue, et al., "Annexin V Disruption Impairs Mechanically Induced Calcium Signaling in Osteoblastic Cells," Bone, Vol 35, No 3) pp. 656-63, (2004)	
	CH	Ackerman, MJ, "Cardiac channelopathies: it's in the genes," Nat. Med., Vol. 10, pp. 463-4 (2004)	
	CI	Bangur, et al., "Mutational analysis of the D1/E1 core helices and the conserved N-terminal region of yeast transcription factor IIB (TFIIB): identification of an N-terminal mutant that stabilizes TATA-binding protein-TFIIB-DNA complexes," Mol. Cell Biol., Vol. 17, pp. 6784-93 (1997)	
	CJ	Brillantes, et al., "Developmental and tissue-specific regulation of rabbit skeletal and cardiac muscle calcium channels involved in excitation-contraction coupline, " Circ. Res., Vol. 75, pp. 503-10 (1994)	
	CK	Brillantes, et al., "Differences in cardiac calcium release channel (ryanodine receptor) expression in myocardium from patients with end-state heart failure caused by ischemic versus dilated cardiomyopathy," Circ. Res., Vol. 71, pp. 18-26 (1992)	
	CL	Chatrath, et al., "Beta-blocker therapy failures in symptomatic probands with genotyped long-QT syndrome," Pediatr. Cardiol., Vol. 25, pp. 459-65 (2004)	
	CM	Che, et al., "Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazipine derivative, JTV-519," Cancer Lett., Vol. 187, pp. 111-9 (2002)	
	CN	Choi, et al., "Spectrum and frequency of cardiac channel defects in swimming-triggered arrhythmia syndromes," Circulation, Vol. 110, pp. 2119-24 (2004)	
	CO	Choi, et al., "Sudden cardiac death and channelopathies: a review of implantable defibrillator therapy," Pediatr. Clin. North Am., Vol. 51, pp. 1289-1303 (2004)	
	CP	Farr, et al., "Sparking the failing heart," N. Engl. J. Med., Vol. 351, pp. 185-7 (2004)	
	CQ	Fitzgerald, et al., "Reduced ryanodine receptor content in isolated neonatal cardiomyocytes compared with the intact tissue," J. Mol. Cell, Cardiol., Vol. 26, pp. 1261-5 (1994)	
	CR	Gillian, et al., "Analysis of expression of the human ryanodine receptor gene in malignant hyperthermia skeletal muscle tissue," Biochem. Soc. Trans., Vol. 19, pp. 46S (1991)	
	CS	Ikemoto, et al., "Regulation of calcium release by interdomain interaction within ryanodine receptors," Front Biosci., Vol. 7, pp. d671-683 (2002)	
	CT	Kirsch, et al., "The roles of annexins and types II and X collagen in matrix vesicle-mediated mineralization of growth plate cartilage," J. Biol. Chem., Vol. 275, pp. 35577-83 (2000)	
↓	CU	Kobrinsky, et al., "Expressed ryanodine receptor can substitute for the inositol 1,4,5-trisphosphate receptor in Xenopus laevis oocytes during progesterone-induced maturation," Dev. Biol., Vol. 172, pp. 531-40 (1995)	
/R.L./	CV	Lehnart, et al., "Immunophilins and coupled gating of ryanodine receptors, "Curr. Top. Med. Chem., Vol. 3, pp. 1383-91 (2003)	

Examiner Signature	/Ruixiang Li/	Date Considered	11/13/2007

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7 of 9

Complete if Known	
Application Number	10/680,988-Conf. #6477
Filing Date	October 7, 2003
First Named Inventor	Andrew R. MARKS
Art Unit	1646
Examiner Name	R. Li
Attorney Docket Number	0019240.00593US1

/R.L./	CW	Lehnart, et al., "Calstabin deficiency, ryanodine receptors, and sudden cardiac death, " Biochem. Biophys. Res. Commun., Vol. 322, pp. 1267-79 (2004)	
	CX	Lesh, et al., "Anti-ryanodine receptor antibody binding sites in vascular and endocardial endothelium," Cir., Res., Vol. 72, pp. 481-8 (1993)	
	CY	Marks, AR, "Calcium channels expressed in vascular smooth muscle," Circulation, Vol. 86, pp. III61-7 (1992)	
	CZ	Marks, AR, "Immunophilin modulation of calcium channel gating," Methods., Vol. 9, pp. 177-87 (1996)	
	CA1	Marks, AR, "Intracellular calcium-release channels: regulators of cell life and death," Am. J. Phsiol., Vol. 272, pp. H597-605 (1997)	
	CB1	Marks, et al., "Molecular cloning and characterization of the Ryanodine receptor/junctional channel complex cDNA from skeletal muscle sarcoplasmic reticulum," Proc. Natl. Acad. Sci. U.S.A., Vol. 86, pp. 8683-7 (1989)	
	CC1	Marks, et al., "Regulation of ryanodine receptors via macromolecular complexes: a novel role for leucine/isoleucine zippers," Tends Cardiovasc. Med., Vol. 12, pp. 166-70 (2002)	
	CD1	Marks, et al., "Surface topography analysis of the ryanodine receptor/junctional channel complex based on proteolysis sensitivity mapping," J. Biol. Chem., Vol. 265, pp. 13143-9 (1990)	
	CE1	Marks, et al., "The ryanodine receptor/junctional channel complex is regulated by growth factors in a myogenic cell line," J. Cell. Biol., Vol. 114, pp. 303-12, (1991)	
	CF1	Maron, et al., "Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases," Circulation, Vol., 109, pp. 2807-16 (2004)	
	CG1	McPhie, et al., "Structure of the hormone binding domain of human beta 1 thyroid hormone nuclear receptor: is is an alpha/beta barrel?" Biochemistry, Vol. 32, pp. 7460-5 (1993)	
	CH1	Nakamura, et al., "Reversal of cisplatin resistance by the 1,4-benzothiazepine derivative, JTV-519," Jpn. J. Cancer Res., Vol. 92, pp. 597-602 (2001)	
	CI1	Ondrias, et al., "FKBP12 modulates gating of the ryanodine receptor/calcium release channel," Ann. N.Y. Acad. Sci., Vol. 853, pp. 149-56 (1998)	
	CJ1	Ondrias, et al., "Single channel properties and calcium conductance of the cloned expressed ryanodine receptor/calcium-release channel, Soc. Gen. Physiol. Serv., Vol. 51, pp. 29-45 (1996)	
	CK1	Paul-Pletzer, et al., "Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor," J. Biol. Chem., Vol. 277, pp. 34918-23 (2002)	
	CL1	Rosemblit, et al., "Intracellular calcium release channel expression during embryogenesis," Dev. Biol., Vol. 206, pp. 163-77 (1999)	
	CM1	Shtifman, et al., "Interdomain interactions within ryanodine receptors regulate Ca2+ spark frequency in skeletal muscle," J. Gen. Physiol., Vol. 119, pp. 15-31 (2002)	
	CN1	Tester, et al., "Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing," Heart Rhythm. Vol. 2, pp. 507-17 (2005)	
	CO1	Tester, et al., "Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: a molecular authopsy of 40 medical examiner/coroner's cases," May Clin. Proc., Vol. 79, pp. 1380-4 (2004)	
	CP1	Timerman, et al., "The ryanodine receptor from canine heart sacroplasmic reticulum is associated with a novel FK-506 binding protein," Biochem. Biophys. Res. Commun., Vol. 198, pp. 701-6 (1994)	
/R.L./	CQ1	Tipton, et al., "My child just fainted: no big deal or sudden-death warning?" Emerg. Med. Serv., Vol. 33, pp. 41-5 (2004)	

Examiner Signature	/Ruixiang Li/	Date Considered	11/13/2007

6090139

PTO/SB/08A/B (09-08)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 of 9

Complete if Known	
Application Number	10/680,988-Conf. #6477
Filing Date	October 7, 2003
First Named Inventor	Andrew R. MARKS
Art Unit	1646
Examiner Name	R. Li
Attorney Docket Number	0019240.00593US1

/R.L./	CR1	Wang, et al., "Retinoic acid stimulates annexin-mediated growth plate chondrocyte mineralization," J. Cell Biol., Vol. 157, pp. 1061-9 (2002)	
	CS1	Wang, W., et al., "Annexin-mediated Ca2+ influx regulates growth plate chondrocyte maturation and apoptosis," J. Biol Chem, Vol. 278, pp. 3762-9 (2003)	
	CT1	Ward, et al., "Defects in ryanodine receptor calcium release in skeletal muscle from post-myocardial infarct rats, "Faseb J. , Vol, 17, pp. 1517-9 (2003)	
	CU1	Wehrens, et al., "Altered function and regulation of cardiac ryanodine receptors in cardiac disease, "Trends Biochem. Sci., Vol. 28, pp. 671-8 (2003)	
	CV1	Wehrens, et al., "Myocardial disease in failing hearts: defective excitation-contraction coupling, "Cold Spring Harb. Symp. Quant. Biol., Vol. 67, pp. 533-41 (2002)	
	CW1	Yamamoto, et al., "Ca2+-dependent dual function of peptice C. The peptide corresponding to the Glu724-Pro760 region (the so-called determinant of excitation-contraction coupling) of the dihydropyridine receptor alpha 1 subunit II-III loop," J. Biol. Chem., Vol. 277, pp. 993-1001 (2002)	
	CX1	Yamamoto, et al., "Peptide probe study of the critical regulatory domain of the cardiac ryanodine receptor," Biochem, Biophys. Res. Commun., Vol. 291, pp. 1102-8 (2002)	
	CY1	Yamamoto, et al., "Spectroscopic monitoring of local conformational changes during the intramolecular domain-domain interaction of the ryanodine receptor," Biochemistry, Vol, 41, pp. 1492-501 (2002)	
	CZ1	Marks, AR, "Arrhythmias of the heart: beyond ion channels," Nat. Medicine, Vol. 9, pp. 263-4, (2003)	
	CA2	Marks, AR, "Calcium and the heart: a question of life and death," J. Clin. Investigation, Vol. 111, pp. 597-600, (2003)	
	CB2	Manzur, et al., "A severe clinical and pathological variant of central core disease with possible autosomal recessive inheritance," Neur. Disorders, Vol. 8, pp. 467-473 (1998)	
	CC2	Swan, et al., "Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations," J. of Card. Electrophysiology, Vol, 16, No. 2, pp. 162-6, (2005)	
	CD2	Culligan, et al., "Drastic reduction of calsequestrin-like proteins and impaired calcium binding in dystrophic mdx muscle," J. Appl. Physiol., Vol. 92, pp. 435-445 (2002)	
	CE2	Dorian, P., "Antiarrhythmic action of beta-blockers: potential mechanisms," J. Cardiovasc. Pharmacol. Therapeut., Vol. 10, pp. S15-S22 (2005)	
	CF2	Morita, et al., "Ca channel blocking activity of JTV-519, a novel protective drug to cytotoxicity," Neuroscience Research, Vol. 31, Supp. 1, p. S65 (1998)	
	CG2	Ishii, et al., "JTV-519, a new cardioprotective drug, and cariporide, synergistically improved post-ischemic contractile recovery in rat," Journal of Molecular and Cellular Cardiology, Vol. 35, Issue 6, p A29 (2002)	
	CH2	Lee, et al., "Sudden unexplained death: evaluation of those left behind," The Lancet, Vol. 362, pp. 1429-1431 (2003)	
	CI2	Behr, et al., "Cardiological assessment of first-degree relatives in sudden arrhythmic death syndrome," The Lancet, Vol. 362, 1457-59 (2003)	
	CJ2	Yamamoto, et al., "T-tubule depolarization-induced local events in the ryanodine receptor, as monitored with the fluorescent conformational probe incorporated by mediation of peptide A," J. Biol. Chem. Vol. 277, pp. 984-92 (2002)	
	CK2	Wang, ZG et al., "Effects of Flecainide and Quinidine on Human Atrial Action Potentials. Role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues," Circulation, Journal of the American Heart Association, Vol. 82, pp. 274-283. 1990	
/R.L./	CL2	Echt et al., "Mortality and morbidity in patients receiving encainide, flecainide, or placebo," The Cardiac Arrhythmia Suppression Trial, N. Engl. J. Med., Vol 324, pp. 781-788. (1991)	

Examiner Signature	/Ruixiang Li/	Date Considered	11/13/2007

6090139

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 9 of 9

Complete if Known	
Application Number	10/680,988-Conf. #6477
Filing Date	October 7, 2003
First Named Inventor	Andrew R. MARKS
Art Unit	1646
Examiner Name	R. Li
Attorney Docket Number	0019240.00593US1

/R.L./	CM2	Schotten et al., "Electrical and contractile remodeling during the first days of atrial fibrillation go hand in hand," Circulation, Vol. 107, pp. 1433-1439. (2003)	
/R.L./	CN2	Shiroshita-Takeshita et al., "Atrial fibrillation: basic mechanisms, remodeling and triggers," J. Interv. Card. Electrophysiol, Vol. 13, pp. 181-193. (2005)	
/R.L./	CO2	Stevenson, W.G. et al., "Sudden death prevention in patients with advanced ventricular dysfunction," Circulation, Vol. 88, pp. 2953-2961. 1993	
/R.L./	CP2	Wilde et al., "Ion Channels, the QT interval, and arrhythmias," Pacing Clin Electrophysiol, Vol. 20, pp. 2048-2051. 1997	
/R.L./	CQ2	Special Report "Preliminary Report: Effect of Encainide and Flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infraction," The New England Jour. of Med., Vol 321, No 6, pp. 406-412. (1989)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Ruixiang Li/	Date Considered	11/13/2007